Pricing Log in Create free account

Clinuvel Pharmaceuticals Ltd. - Sponsored ADR (CUVL) vs SAB Biotherapeutics, Inc. (SABS)

Clinuvel Pharmaceuticals Ltd. - Sponsored ADR and SAB Biotherapeutics, Inc. are both Biotechnology companies. Clinuvel Pharmaceuticals Ltd. - Sponsored ADR and SAB Biotherapeutics, Inc. are of similar size ($273.0M and $257.5M).

Valuation

Metric CUVL SABS Biotechnology median
P/E — n/m 10.60
P/S — 148.49 9.40
P/B — 1.13 2.13
Price to free cash flow — n/m 25.18
EV/EBITDA — n/m 0.66
EV/Sales — 87.29 9.02
Earnings yield — (6.25%) (32.88%)
Free cash flow yield — (23.77%) (23.13%)

Profitability

Metric CUVL SABS Biotechnology median
Gross margin — 100.00% 68.51%
Operating margin — 0.00% 0.00%
Net margin — 0.00% 0.00%
Free cash flow margin — 0.00% 0.00%
Return on equity — (34.27%) (51.96%)
Return on assets — (28.97%) (46.06%)
Return on invested capital — (38.97%) 0.00%

Growth

Metric CUVL SABS Biotechnology median
Revenue growth (TTM) — (60.26%) 6.76%
EPS growth (last fiscal year) — 78.53% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — (26.69%) 0.00%

Health

Metric CUVL SABS Biotechnology median
Debt to equity — 0.01 0.00
Current ratio — 9.22 4.97
Net debt to EBITDA — 2.03 1.01

Dividend

Metric CUVL SABS Biotechnology median
Dividend yield 0.56% — 0.41%
Payout ratio — — —

Size

Metric CUVL SABS Biotechnology median
Market cap 257.50m 272.97m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack